Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CRISPR Anchor screening of a barcoded library in cells treated with standard of care neuroblastoma drugs

ABSTRACT: CRISPR Anchor screening of a barcoded library in cells treated with standard of care neuroblastoma drugs

PROVIDER: PRJNA929273 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23267800_1.fastq.gz	Fastqsanger.gz
	SRR23267800_2.fastq.gz	Fastqsanger.gz
	SRR23267900_1.fastq.gz	Fastqsanger.gz
	SRR23267900_2.fastq.gz	Fastqsanger.gz
	SRR23268000_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 676

Similar Datasets

CRISPR Anchor screening of a barcoded library in cells treated with standard of care neuroblastoma drugs

Project description:Neuroblastoma cells were treated with a barcoded library of >600 genes and one of several standrard of care neuroblastoma compounds (or vehicle control)

2023-09-28 | GSE223991 | GEO

Transcription profling of a yeast molecular barcoded ORF library

Project description:I used Affy Tag4 array as a readout of the molecular barcoded yeast orf library<br>

2009-07-02 | E-MEXP-2077 | biostudies-arrayexpress

Analysis of diversity in barcoded virus library

Project description:Analysis of diversity in barcoded virus library

| PRJNA630756 | ENA

Analysis of diversity in barcoded plasmid library

Project description:Analysis of diversity in barcoded plasmid library

| PRJNA630750 | ENA

NICHD-2019-POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care

Project description:NICHD-2019-POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care

| PRJNA758451 | ENA

NICHD-2019-POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care

Project description:NICHD-2019-POP02: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care

| PRJNA758450 | ENA

Transcriptional profiling of MCF7 cells treated with H3B05942, E2, or standard of care compounds

Project description:The objective of this experiment was to compare the affect of H3B-5942 treatment on global gene expression and to compare to treatment with standard of care agents tamoxifen and fulvestrant.

2018-06-12 | GSE115609 | GEO

Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies

Project description:Venetoclax is the first example of personalized medicine for multiple myeloma (MM), with meaningful clinical activity as a monotherapy and in combination in myeloma patients harboring the t(11:14) translocation. However, despite the high response rates and prolonged PFS, a significant proportion of patients eventually relapse. Here, we aimed to study adaptive molecular responses after the acquisition of venetoclax resistance in sensitive t(11:14) MM cell models. We therefore generated single-cell venetoclax-resistant t(11:14) MM cell lines and investigated the mechanisms contributing to resistance as well as the cells’ sensitivity to other treatments. Our data suggests that acquired resistance to venetoclax is characterized by reduced mitochondrial priming and changes in BCL-2 family proteins’ expression in MM cells, conferring broad resistance to standard-of-care anti-myeloma drugs. However, our results show that the resistant cells are still sensitive to immunotherapeutic treatments, highlighting the need to consider appropriate sequencing of these treatments following venetoclax-based regimens.

2024-06-06 | GSE269245 | GEO

EMS02 barcoded yeast collection

Project description:EMS02 barcoded yeast collection

| PRJEB90659 | ENA

Transcriptional profiling of Ishikawa cells treated with H3B-5942, E2, or standard of care compounds

Project description:The objective of this experiment was to determine the affect of H3B-5942 treatment on global gene expression in an estrogen-deprived setting (agonist mode) and to compare to treatment with a saturated analog of H3B-5942, GDC-0810, and standard of care agents tamoxifen and fulvestrant.

2018-06-12 | GSE115608 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data